Authors
Latest:
Oncology Clinical Trials During the COVID-19 PandemicABSTRACT The coronavirus disease 2019 (COVID-19) pandemic has rapidly spread all over the world in the past several months. No effective treatment for COVID-19 has been established. High transmissibility and considerable mortality rates have forced many national governments to implement quarantine measures. Many patients with cancer rely on clinical trials to receive their oncologic care, but the routine conduct of clinical trials has substantially changed because of the COVID-19 pandemic. The oncology research community should implement formal policies based on the guidance given from regulatory agencies, with the goal of minimizing the risks of COVID-19 infection while maintaining appropriate oncologic treatments for patients during this pandemic.
Latest:
Experts Discuss Personalized ctDNA Assays to Predict Immunotherapy ResponseCancerNetwork® recaps a Between the Lines journal club program with George Ansstas, MD, and Firas B. Badin, MD.
Latest:
How to Treat Metastatic Malignant Triton Tumor in an AdolescentA systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.
Latest:
Evaluating Treatment Options and the Multidisciplinary Care of Ocular Toxicities of MEK InhibitorsDavid L. DeRemer, PharmD, BCOP, and Bently P. Doonan, MD, MS, share a perspective on ocular toxicities associated with MEK inhibition.
Latest:
FDA Approves Liso-Cel for Relapsed/Refractory CLL/SLLPatients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma can now receive lisocabtagene maraleucel after the FDA approved the drug, which was based on the phase 1/2 TRANSCEND CLL trial.
Latest:
Ginzburg Discusses Most Interesting Presentations From ASH 2021At the 2021 ASH Annual Meeting, Yelena Ginzburg, MD, spoke about presentations she found most groundbreaking.
Latest:
Treatment of Locally Advanced Cervical Cancer With Kidney Failure and ComorbiditiesIn this edition of Clinical Quandaries Eder A. Arango Bravo, MD, and colleagues present a 63 year old woman who has cervical cancer with kidney failure and additional comorbidities.
Latest:
Ian D. Davis, MBBS, PhD, Reviews Interesting Data From TheraP Trial of 177Lu-PSMA-617 in mCRPC at 2022 ASCOIan D. Davis, MBBS, PhD, spoke about the TheraP study which evaluated 177Lu-PSMA-617 vs cabazitaxel in patients with metastatic castration-resistant prostate cancer.
Latest:
The AML Treatment HorizonExperts on acute myeloid leukemia offer closing thoughts and discuss emerging treatments in the field.
Latest:
Advancing Pancreatic Cancer Care Through Intraoperative Radiation TherapyExperts from Vanderbilt Medical Center review mechanisms, supporting data, and patient cases associated with the use of IORT in pancreatic cancer.
Latest:
Future Perspectives in the Treatment of Chronic Lymphocytic LeukemiaConcluding their discussion, Drs Advani, Parrondo, and Chanan-Khan conclude that second-generation BTK inhibitors are the preferred first-line treatment in patients with chronic lymphocytic leukemia due to better efficacy and lower cardiovascular risk, with emerging therapies promising even better outcomes.
Latest:
The Role of Molecular Testing in Treatment Decisions for NSCLCThis video segment explores the critical role of biomarker testing in identifying patients with ALK-positive NSCLC, discussing the clinical characteristics that guide the use of ALK inhibitors and addressing challenges in implementing comprehensive molecular testing in community settings.
Latest:
Reviewed in ONCOLOGY®: Gender Representation on Guideline PanelsThis issues Publisher's Note focuses on a manuscript regarding gender equity on oncology guideline panels.
Latest:
Twenty Years of Advancing Discoveries and Treatment of Mantle Cell LymphomaIn 2023, the Lymphoma Research Foundation hosted the Mantle Cell Lymphoma Scientific Consortium and Workshop to discuss treatment advancements in the field.
Latest:
Strategies for Overcoming Disparities for Patients With Hematologic Malignancies and for Improving Enrollment on Clinical TrialsA multitude of factors contributes to cancer disparities. Addressing these disparities among racial/ethnic minority populations with blood cancers requires multilevel models of the interactions between relevant factors and the performance of translational research that uses knowledge of cancer biology to develop and test the feasibility of interventions that can impact human endpoints. To be effective, efforts should be made to advance these research findings to applications that can transform clinical practice and health care delivery. We reviewed the literature to define a framework for overcoming disparities for patients with hematologic malignancies and to improve patient enrollment in clinical trials.
Latest:
Clinical Pearls on Treating Patients with NRG1 FusionsTeresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, offer key takeaways and conclude their discussion by offering advice for clinicians treating patients with NRG1 fusion–positive malignancies.
Latest:
ctDNA May Replace Bone Marrow Exams in Multiple Myeloma, Expert SaysAn expert from Stanford Medicine that the goal behind a study characterizing circulating tumor DNA and its predictive value is to eventually replace blood marrow exams with a blood draw for those with multiple myeloma.
Latest:
Radiologic Assessment May Be Used Before First Line Therapy for mccRCCA review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
Latest:
Treatment Experience for a Patient With GVHDA patient with GVHD chronicles his treatment experience, and GVHD experts share thoughts on how to approach treatment.
Latest:
Caring for Patients With Serious Mental Illness: Guide for the Oncology ClinicianVeronica B. Decker, DNP, MBA, APRN, PMHCNS-BC, and colleagues discuss how to care for patients with cancer and serious mental illness.
Latest:
Evolving Role of Autologous Stem Cell Transplantation for Light Chain Amyloidosis in the Modern EraMuhamed Baljevic, MD, considers the role of autologous stem cell transplantation for light chain amyloidosis in a peer perspective accompanying an article by Iuliana Vaxman, MD, and Angela Dispenzieri, MD.
Latest:
Assessing Patient Eligibility for CAR-T TherapyThis segment explores factors influencing patient candidacy for CAR-T therapy, including age, fitness, and relapse specifics, and evaluates key findings from the KarMMa trials to compare ide-cel with other second-line treatment options for multiple myeloma.
